BPI21-006: Timing of NTRK Gene Fusion Testing and Treatment Modifications Following NTRK+ Status Among U.S. Oncologists Treating NTRK+ Patients

View More View Less
  • 1 Cardinal Health Specialty Solutions, Dublin, OH
  • 2 Bayer U.S. LLC, Whippany, NJ
Restricted access

Corresponding Author: Landon Z. Marshall, PharmD, PhD
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 131 131 45
PDF Downloads 155 155 27
EPUB Downloads 0 0 0